Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .
Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.
This study describes the changes in risk factors for coronary heart disease in obese persons with syndrome X after orlistat-assisted weight loss . Data were available for 1,700 patients who completed 52 weeks of weight loss ; 128 were defined as having syndrome X by being in the quintile with the highest plasma triglyceride levels ( > 2.2 mM/L ) and the lowest high-density lipoprotein cholesterol ( HDL , < 1.0 mM/L ) concentrations . Initial characteristics of those with syndrome X were similar to the 119 subjects ( non-syndrome X ) in the lowest quintile of plasma triglyceride ( < 0.975 mM/L ) and highest quintile of HDL cholesterol ( > 1.5 mM/L ) . Subjects were placed on a calorie-restricted diet , and r and omized to receive orlistat or placebo . Initial values were higher in those with syndrome X for diastolic blood pressure ( p = 0.03 ) , plasma insulin ( p = 0.0001 ) , triglyceride ( p = 0.0001 ) concentrations , and ratio of low-density lipoprotein cholesterol to HDL cholesterol ( p = 0.0001 ) , and were lower for HDL cholesterol ( p = 0.001 ) concentrations . Weight loss was greater in both groups of orlistat-treated patients ( p = 0.026 ) ; in those with syndrome X , it was associated with a significant reduction in plasma insulin ( p = 0.019 ) and triglyceride ( p = 0.0001 ) concentrations , an increase in HDL cholesterol concentration , and a decrease in low-density lipoprotein/HDL cholesterol ratio ( p = 0.0001 ) . There were no significant changes in plasma insulin , triglycerides , or HDL cholesterol concentration in the non-syndrome X group . In conclusion , weight loss attenuates coronary heart disease risk factors in obese persons with syndrome X , and the risk factor reduction is enhanced with administration of orlistat
Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .